The mice fed Naturex’s Glucevia extract had lower blood glucose levels two hours after feeding compared to the control group and ‘chronic administration’ of it in mice on high-fat diets reduced fatty liver incidence by 66.7%.
Researchers from the University of Murcia in southern Spain randomly divided 20 5-week old mice into ‘standard chow’ and chow fortified with Glucevia at 0.07%.
“A significant reduction in plasma levels of triglycerides accompanied by a reduction in fasting plasma glucose and body weight were found in Zucker rats fed with the extract for 5 weeks,” the researchers found.
The intervention lasted 28 weeks with the researchers suggesting it can be an effective treatment for non-alcoholic fatty liver disease.
“…this study suggests that long term administration Glucevia prevents hepatic steatosis in [diabetic] mice, probably mediated by glucose homeostasis and insulin resistance improvements.”
They called for further studies “to generate mechanistic insight on steatosis prevention and to identify companion biomarkers…”.
Naturex R&D director Dr Antoine Bily said: “We will continue investigating Glucevia’s hepatoprotective function because non-alcoholic fatty liver disease is the main manifestation of insulin resistance and is linked to metabolic syndrome."
“Currently, only a few preventive supplements exist and there is no evidence-based approved therapy to manage this common chronic disease in Western countries.”
Journal of Diabetes & Metabolism
March 2015 (doi: 10.4172/2155-6156.1000527)
‘Preventive Effect of a Fraxinus Excelsior L Seeds/Fruits Extract on Hepatic Steatosis in Obese Type 2 Diabetic Mice’
Authors: Garcia FG, Flanagan J, Molina OG, Vivo VV, Carrillo NG, et al.